眼内淋巴瘤患者化学药物治疗后的眼底变化

Abstract
Figure/Table
References
Related Citation (15)

Download: PDF (1694 KB) HTML (1 KB)
Export: BibTeX | EndNote (RIS)

Abstract Objective To observe the fundus characteristics and changes of patients with intraocular lymphoma after chemotherapy. Methods A retrospective analysis of 11 patients (15 eyes) with intraocular lymphoma who were treated in the Department of Ophthalmology of the First Center of Chinese PLA General Hospital from January 2015 to December 2021 involved 7 males and 4 females, ranging in age from 47 to 67, with an average age of 55.9. Results Eleven patients (11 eyes) were diagnosed with lymphoma at other sites combined with intraocular lymphoma. After local chemotherapy or combined systemic treatment, ocular lymphoma has a good atrophy effect, and no central nervous system involvement has been observed so far. Chemotherapy-related retinopathy occurred in 7 patients (7 eyes) and optic neuropathy in 7 patients (9 eyes) within 2 years. No progressive changes were observed in fundus for 1 year after symptomatic treatment, and the condition was stable. Three patients (6 eyes) were diagnosed with lymphoma at other sites and received chemotherapy. Chemotherapy-associated optic neuropathy and chemotherapy-associated retinopathy were diagnosed within 1 year. The patients were followed up for 1 year after symptomatic treatment. Fundus lesions did not progress and the condition was stable. One patient (1 eye) developed idiopathic retinal hemorrhage in one eye within 1 year after diagnosis of lymphoma elsewhere and received chemotherapy. Symptomatic ophthalmologic treatment was given. During the 1-year follow-up, the fundus lesions did not progress and the condition was stable. Conclusions The incidence of chemotherapeutic optic neuroretinopathy is very high in patients with systemic lymphoma combined with intraocular lymphoma, whether receiving intraocular chemotherapy or intraocular chemotherapy combined with systemic chemotherapy. Eye and systemic symptomatic treatment can stabilize or slow down the occurrence and progression of the fundus lesions and reduce central nervous involvement.

Key words： lymphoma chemotherapy fundus lesions

Received: 20 May 2022

ZTFLH:

R739.7

	Service

	E-mail this article
	Add to my bookshelf
	Add to citation manager
	E-mail Alert
	RSS
	Articles by authors
	LI Ying
	ZHANG Hongtao

Cite this article:

LI Ying,ZHANG Hongtao. Fundus changes of patients with intraocular lymphoma after chemotherapy[J]. Med. J. Chin. Peop. Armed Poli. Forc., 2023, 34(1): 22-25.

URL:

http://journal08.magtechjournal.com/Jwk_wjyx/EN/ OR http://journal08.magtechjournal.com/Jwk_wjyx/EN/Y2023/V34/I1/22

[1]	Davis J L. Intraocular lymphoma: a clinical perspective[J]. Eye(Lond), 2013, 27(2):153-162.
[2]	Kvopka M, Lake S R, Smith J R. Intraocular chemotherapy for vitreoretinal lymphoma: a review[J]. Clin Exp Ophthalmol, 2020, 48(2): 240-248.
[3]	Sagoo M S, Mehta H, Swampillai A J, et al. Primary intraocular lymphoma[J]. Surv Ophthalmol, 2014, 59(5): 503-516.
[4]	Bever G J, Kim D J, Afshar A R, et al. Therapeutic vitrectomy as an adjunct treatment to systemic chemotherapy for intraocular lymphoma[J]. Retin Cases Brief Rep, 2020, 14(2):116-119.
[5]	Smith J R, Pe’er J, Belfort R N, et al. Proceedings of the Association for Research in Vision and Ophthalmology and Champalimaud Foundation Ocular Oncogenesis and Oncology Conference[J]. Transl Vis Sci Technol, 2018, 8(1):9.
[6]	陈佳梅,罗波,罗茜茜,等. 我国血管内大B细胞淋巴瘤的临床亚型、诊治及预后分析[J].中国癌症防治杂志,2021,13(3): 288-294.
[7]	武文韬,李达宁,郑帅,等. 1990—2019年中国霍奇金淋巴瘤流行趋势和疾病负担分析[J]. 医学新知,2021,31(6):433-440.
[8]	肖婷婷,缪振忠,李玉生等.霍奇金淋巴瘤并发眼部伪装综合征1例[J].中华眼底病杂志,2019(2):194-195.
[9]	Peterson K, Gordon K B, Heinemann M H, et al. The clinical spectrum of ocular lymphoma[J]. Cancer, 1993, 72(3): 843-849.
[10]	Rooij J L, Tokarska K A, Loon N H, et al. Central nervous system progression in primary vitreoretinal lymphoma with bilateral and unilateral involvement: a systematic review and meta-analysis[J]. Cancers(Basel), 2022, 14(12): 2967.
[11]	石燕红, 陶勇.原发玻璃体视网膜淋巴瘤的过去现在和未来[J]. 中华眼科学杂志,2021, 2(11): 54-59.
[12]	Chan C C, Rubenstein J L, Coupland S E, et al. Primary vitreoretinal lymphoma: a report from an international primary central nervous system lymphoma collaborative group symposium[J]. Oncologist, 2011, 16(11): 1589-1599.
[13]	Hoang X K, Bessell E, Bromberg J, et al.Diagnosis and treatment of primary CNS lymphoma in immune competent patients: guidelines from the european association for neuro-oncology[J].Lancet Oncol, 2015, 16(7) : 322-332.
[14]	Hashida N, Ohguro N, Nishida K. Efficacy and complications of intravitrealrituximab injection for treating primary vitreoretinal lymphoma[J]. Transl Vis Sci Technol, 2012, 1(3) : 15-18.
[15]	Castellino A, Pulido J S, Johnston P B, et al. Role of systemic high-dose methotrexate and combined approaches in the management of vitreoretinal lymphoma: A single center experience 1990-2018[J]. Am J Hematol, 2019, 94(3): 291-298.